Museum Centre Vapriikki: Ancient DNA Reveals 800-year-old Family Link in Medieval Finland
7.8.2025 14:05:00 CEST | Business Wire | Press Release
Ancient DNA research led by the Museum Centre Vapriikki in Tampere, Finland, in collaboration with the universities of Turku and Helsinki, has produced new insights into kinship, health, and population continuity in medieval and early modern Finland. Published in the peer-reviewed journal iScience, the research presents results from 25 individuals in Finland – a significant result in a country where acidic soils often lead to poor preservation of bones and genetic material.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250807066724/en/
The woman’s grave in Vilusenharju, Tampere was discovered in 1962, and the man’s grave in Ristiänmäki, Pälkäne in 1982. Ancient DNA research has now revealed that the deceased were siblings. Illustrations by Veronika Paschenko. Photo by Vapriikki.
Researchers successfully recovered DNA from individuals buried between the 12th and 19th centuries at three cemeteries in the Tampere region. The study is part of Vapriikki’s research project that applies scientific methods to investigate the region’s past.
Family ties and genetic continuity
One of the study’s findings was the discovery of full siblings buried 30 kilometers apart. A woman buried in Tampere and a man in Pälkäne, both from the 12th century, were confirmed to be sister and brother.
“This provides tangible evidence of family connections between different communities,” says Dr. Ulla Nordfors, researcher at Vapriikki.
Comparisons with over 4,000 modern Finnish genomes from the Finnish Institute for Health and Welfare’s biobank revealed that the ancient individuals from Tampere region share the closest genetic affinities with people living in the same region today.
“These results point to a remarkable degree of genetic continuity in the area since at least the early Middle Ages,” says Sanni Peltola, a doctoral researcher at the University of Helsinki.
Additional genetic links were detected between Finnish individuals and previously published ancient genomes from Scandinavia and the Lake Ladoga region, providing evidence of mobility and cultural contacts in the Viking Age and beyond.
“Although the dataset is relatively small, the findings clearly show that medieval Finland was not isolated,” Peltola notes. “It was part of the wider networks of interaction that shaped northern Europe.”
Health and traits revealed
The analysis also recovered microbial DNA that sheds light on health in past populations. Bacteria in 13th-century dental calculus included species linked to both oral and systemic health. DNA from a post-medieval man revealed the presence of Treponema, a bacterial genus that includes the causative agent of syphilis.
Hereditary traits were also uncovered. Most individuals were lactose tolerant, like modern Finns, and a 12th-century man likely had corneal dystrophy, a degenerative eye disease that may have impaired his vision.
“Genes cannot capture the full complexity of a person and their life, but learning about health, traits, and family ties can help us see ancient people as individuals who once lived, felt, and experienced the world,” says Nordfors. “When interpreted within their archaeological and historical context, these details allow us to approach the past on a more human level.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250807066724/en/
Contacts
Ulla Nordfors, ulla.nordfors@tampere.fi
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom